The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Amyotrophic Lateral Sclerosis (ALS) Market Research Report 2025
Synopsis
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ 300 million in 2023 and is anticipated to reach US$ 379.1 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS).
Report Scope
The Amyotrophic Lateral Sclerosis (ALS) market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis (ALS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Amyotrophic Lateral Sclerosis (ALS) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ 300 million in 2023 and is anticipated to reach US$ 379.1 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS).
Report Scope
The Amyotrophic Lateral Sclerosis (ALS) market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis (ALS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Amyotrophic Lateral Sclerosis (ALS) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Amyotrophic Lateral Sclerosis (ALS) Market Overview
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
1.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Type (2024-2030)
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Estimates and Forecasts
1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2030
1.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2030
1.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Amyotrophic Lateral Sclerosis (ALS) Market Competition by Manufacturers
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturers (2019-2024)
2.4 Global Amyotrophic Lateral Sclerosis (ALS) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Type & Application
2.7 Amyotrophic Lateral Sclerosis (ALS) Market Competitive Situation and Trends
2.7.1 Amyotrophic Lateral Sclerosis (ALS) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue
2.7.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Amyotrophic Lateral Sclerosis (ALS) Retrospective Market Scenario by Region
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2019-2030
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2019-2024
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2025-2030
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2019-2030
3.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2019-2024
3.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2025-2030
3.4 North America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.5.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.5.3 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.6.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.6.3 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.7.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.7.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.8.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2030)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2025-2030)
4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2030)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2030)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2024)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2025-2030)
4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2030)
4.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2030)
5.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024)
5.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2025-2030)
5.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2030)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2030)
5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2024)
5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2025-2030)
5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2019-2030)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Mitsubishi Tanabe Pharma
6.1.1 Mitsubishi Tanabe Pharma Corporation Information
6.1.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.1.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Mylan Pharma
6.3.1 Mylan Pharma Corporation Information
6.3.2 Mylan Pharma Description and Business Overview
6.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.3.5 Mylan Pharma Recent Developments/Updates
6.4 Apotex
6.4.1 Apotex Corporation Information
6.4.2 Apotex Description and Business Overview
6.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.4.5 Apotex Recent Developments/Updates
6.5 Glemark Generics
6.5.1 Glemark Generics Corporation Information
6.5.2 Glemark Generics Description and Business Overview
6.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.5.5 Glemark Generics Recent Developments/Updates
6.6 Covis Pharma
6.6.1 Covis Pharma Corporation Information
6.6.2 Covis Pharma Description and Business Overview
6.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.6.5 Covis Pharma Recent Developments/Updates
6.7 Sun Pharma
6.6.1 Sun Pharma Corporation Information
6.6.2 Sun Pharma Description and Business Overview
6.6.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.7.5 Sun Pharma Recent Developments/Updates
6.8 Lunan Pharma
6.8.1 Lunan Pharma Corporation Information
6.8.2 Lunan Pharma Description and Business Overview
6.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.8.5 Lunan Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Amyotrophic Lateral Sclerosis (ALS) Industry Chain Analysis
7.2 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
7.4 Amyotrophic Lateral Sclerosis (ALS) Sales and Marketing
7.4.1 Amyotrophic Lateral Sclerosis (ALS) Sales Channels
7.4.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
7.5 Amyotrophic Lateral Sclerosis (ALS) Customers
8 Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
8.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
8.2 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
8.3 Amyotrophic Lateral Sclerosis (ALS) Market Challenges
8.4 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
